临床儿科杂志 ›› 2020, Vol. 38 ›› Issue (7): 530-.doi: 10.3969/j.issn.1000-3606.2020.07.012

• 综合报道 • 上一篇    下一篇

儿童尤文肉瘤家族肿瘤50 例临床病理特点及预后因素分析

董玉双, 谈珍, 张勤, 袁晓军   

  1. 上海交通大学医学院附属新华医院小儿血液肿瘤科(上海 200092)
  • 发布日期:2020-07-14
  • 通讯作者: 袁晓军 电子信箱: yuanxiaojun@xinhuamed.com.cn

Analysis of clinicopathological characteristics and prognostic factors of Ewing’s sarcoma family tumor in 50 children

DONG Yushuang, TAN Zhen, ZHANG Qin, YUAN Xiaojun   

  1. Department of Pediatric Hematology Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Published:2020-07-14

摘要:  目的 分析儿童尤文肉瘤家族肿瘤(ESFT)的临床、病理、分子表型特点及预后。方法 回顾分析2008年8 月至2018年12月经病理诊断为ESFT的50例患儿临床及病理资料。结果 50例患儿中,男29例、女21例;中位发病年 龄8岁(生后7天~14岁),中位随访时间35个月(1~137个月)。23例患儿的首发症状为局部疼痛,21例为无痛性肿块(其 中19例肿块≥8 cm),6例表现为双下肢运动障碍、发热、打鼾等。15例初诊时已发生转移。50例患儿经免疫组织化学检测 提示100%(50/50)CD99阳性、80%(20/25)FLI-1阳性、80%(4/5)NKX2.2阳性;32例(32/35,91%)存在EWSR1融合 基因易位。50例患儿中32例接受手术加化疗及放疗的联合治疗。 3年总体生存率(3y-OS)为(68.2±6.9)%,其中无转移 组3y-OS为(78.7±7.2)%,转移组3y-OS为(20.6±16.1)%(P<0.001)。Log-Rank检验结果显示无转移、肿瘤直径<8 cm、原发于四肢、手术为完整切除、联合治疗以及联合放疗的患儿生存时间更长,差异均有统计学意义(P<0.05)。Cox回 归分析显示,远处转移、手术未完整切除、未接受联合治疗是导致ESFT患儿预后差的独立风险因素(P<0.05)。 结论 结 合EWSR1基因易位及CD99、FLI-1、NKX2.2分子表达可提高ESFT诊断的正确率;初诊时远处转移、肿块未完整切除、 未接受联合治疗是影响患者预后的不良因素。

关键词: 尤文肉瘤家族肿瘤;  临床特点;  病理;  分子表型;  预后

Abstract: Objective To explore the clinical, pathological, molecular phenotypic characteristics and prognosis of childhood Ewing's sarcoma family tumor (ESFT). Methods The clinical and pathological data of ESFT in 50 children from August 2008 to December 2018 were analyzed retrospectively. Results In the 50 children (29 males and 21 females), median age at onset was 8 years (7 days to 14 years) and the median follow-up time was 35 months (1 to 137 months). The first symptom of 23 cases was local pain, 21 cases presented with painless mass (19 cases had mass ≥ 8 cm), and 6 cases presented with lower limb dyskinesia, fever, snoring, etc. Fifteen children had metastasis at initial diagnosis. Immunohistochemistry showed that 100% of the 50 children (50/50) were positive for CD99, 80% (20/25) for FLI-1 and 80% (4/5) for NKX2.2. Thirty-two children (32/35, 91%) had EWSR1 fusion gene translocation. Thirty-two of the 50 children received surgery combined with chemotherapy and radiotherapy. The 3-year overall survival rate (3y-OS) was (68.2±6.9) %, including (78.7±7.2) % in the non-metastatic group and (20.6±16.1) % in the metastatic group (P<0.001). The Log-Rank test results showed that children with no metastasis, tumor <8 cm in diameter, limb being primary, complete resection, combined treatment and combined radiotherapy had a longer survival time, and the differences were statistically significant (P<0.05). Cox regression analysis showed that distant metastasis, incomplete surgical resection and no combination therapy were independent risk factors for poor prognosis of ESFT children (all P<0.05). Conclusions Combination of EWSR1 gene translocation and CD99, FLI-1, NKX2.2 molecular expression can improve the accuracy of ESFT diagnosis. Distant metastasis, incomplete resection of the mass and failure to receive multidisciplinary treatment at the first diagnosis are the adverse factors of the prognosis of the patients.

Key words: Ewing sarcoma family tumor; clinical feature; pathology; molecular phenotype; prognosis